0000899243-17-012363.txt : 20170508 0000899243-17-012363.hdr.sgml : 20170508 20170508203732 ACCESSION NUMBER: 0000899243-17-012363 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170504 FILED AS OF DATE: 20170508 DATE AS OF CHANGE: 20170508 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Altimmune, Inc. CENTRAL INDEX KEY: 0001326190 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 202726770 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 19 FIRSTFIELD ROAD CITY: GAITHERSBURG STATE: MD ZIP: 20878 BUSINESS PHONE: 2406541450 MAIL ADDRESS: STREET 1: 19 FIRSTFIELD ROAD CITY: GAITHERSBURG STATE: MD ZIP: 20878 FORMER COMPANY: FORMER CONFORMED NAME: PHARMATHENE, INC DATE OF NAME CHANGE: 20071016 FORMER COMPANY: FORMER CONFORMED NAME: HEALTHCARE ACQUISITION CORP DATE OF NAME CHANGE: 20050505 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Schafer Klaus CENTRAL INDEX KEY: 0001705904 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32587 FILM NUMBER: 17824147 MAIL ADDRESS: STREET 1: 19 FIRSTFIELD RD., SUITE 200 CITY: GAITHERSBURG STATE: MD ZIP: 20878 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-05-04 0 0001326190 Altimmune, Inc. NASDAQ:ALT 0001705904 Schafer Klaus 19 FIRSTFIELD ROAD, SUITE 200 GAITHERSBURG MD 20878 1 0 0 0 Common Stock, par value $0.0001 2017-05-04 4 A 0 5998 A 5998 D Stock Option (option to buy) 0.08 2017-05-04 4 A 0 4775 A 2017-05-04 2022-07-04 Common Stock, par value $0.0001 4775 4775 D Stock Option (option to buy) 0.08 2017-05-04 4 A 0 1791 A 2017-05-04 2022-07-04 Common Stock, par value $0.0001 1791 1791 D Stock Option (option to buy) 0.08 2017-05-04 4 A 0 1791 A 2017-05-04 2022-12-31 Common Stock, par value $0.0001 1791 1791 D Stock Option (option to buy) 0.59 2017-05-04 4 A 0 1791 A 2017-05-04 2023-12-31 Common Stock, par value $0.0001 1791 1791 D Acquired pursuant to the Agreement and Plan of Merger, dated as of January 18, 2017 (as amended on March 29, 2017, the "Merger Agreement"), pursuant to which a wholly-owned subsidiary of the Issuer merged with and into Altimmune, Inc. ("Altimmune"). Pursuant to the Merger Agreement, the then outstanding shares of Altimmune's capital stock was converted into the right to receive a number of shares of the Issuer's common stock, par value $0.0001 on a 0.749106:1 basis upon the closing of the merger. Pursuant to the terms of the Merger Agreement, the Issuer assumed all outstanding options to purchase shares of Altimmune capital stock on a 0.749106:1 basis upon closing of the merger. /s/ Ori Solomon, Attorney in fact for Klaus Schafer 2017-05-08